AMA Approves Vermillion MAAA Category 1 Code for OVA1; Will it Improve Reimbursement? GenomeWeb (Medicare)

"Medicare reimbursement has been a point of concern for the company. As previously covered in PGx Reporter sister publication ProteoMonitor, there have been reports that Medicare has been denying OVA1 claims at a rate of more than 80 percent (PM 12/23/2011)."